{"name":"Splash Pharmaceuticals, Inc.","slug":"splash-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxNYlZFc3Q1MTdCblpJR3o1OHlkMExHNzQ0bllwN2dLdW40eUVpamMyaWRJMFlieDNJdzZHWmFXYmhZajBrTzFsMmtoUmJDd195YXFMYW9INklNUm9fVVFySmdfSUJ3bG5WcHdLSWtLOVVpNTVqY0l4Z2R3WW9xRUUzYzFQUUZuOGpVN0VmakZlTDEwQjIyUkw2QUdVRFp6anF4MzRseHhsOVRScDd3STdMQnBhbE4yVjJ1dVR0dXRaNnBmMEFIVjVxMmdXSHZHMHFxY2dxZG1ZUlZNV2gzcWlHUHlHanhGaVRqams0UU5RRTRHY25QekNIaHFpbVljUDlncmFTTGRBbzhCd1ZENmNoeTI5a2RYWnhzNGlwYmJIelg5Z2NN?oc=5","date":"2026-04-03","type":"pipeline","source":"Bluefield Daily Telegraph","summary":"RARE Deadline: Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Bluefield Daily T","headline":"RARE Deadline: Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders with Losses in Excess of ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPclFrV1JOc1VSWFdnRGRidm1WZnI4T1RNTzFYVFd6Z0p5WUszNWl4UHZzZEFhU1FxZFg2aGpVQW91TEVld0lLLTFOZHB6aDl3akZyUjJxbjZNVEI5QkZvdDFDTUpxWnlaUlRoNXBSLWRtWGpfMkRFeG5Ta25oRkp3d2IxQzNYam1pckNJZkRMNUlhdG5rZm00Zl9n?oc=5","date":"2026-02-12","type":"pipeline","source":"BioSpace","summary":"BioMarin Bet on Amicus To Ease Voxzogo’s Decline. Will It Work? - BioSpace","headline":"BioMarin Bet on Amicus To Ease Voxzogo’s Decline. Will It Work?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPVVROU1BKQS1qSnhTQmcwSlRObTNJZEFQZnY3M0pFeUNFSDdWamxkdHNyZ01jQnpmaGF6dXdHcmhrTjdkMHZHaEZMNzgwNm5aNGdxM3pYSGxQRkE4dUlxMm50ZkNtTjRsb2xxTTVwbU1vUnB2ZEZfVTRIMXRJNWlWUE1ISXU1WkVwalVlMF9tWUFjU3RzWWRN?oc=5","date":"2026-02-10","type":"pipeline","source":"Healthcare Brew","summary":"Big Pharma tackles Super Bowl advertising - Healthcare Brew","headline":"Big Pharma tackles Super Bowl advertising","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxONFJzbEdSemhjcENuSFFxcmZpc1F0ZkxXbUhIcThJcmFIeWdzYWx0MmZqR285QlhiNmZjN2gwMS1xNndsSzg1Qm45SUNmaHZXY1dtQ2lScmZRVFFwRTdicE9PYVFnUmFwcmVROVZod1c0eDM2M25WRURmRjYtQzJKZ0FmeEwtMlNKdEFYMQ?oc=5","date":"2025-11-04","type":"pipeline","source":"Modern Healthcare","summary":"Inside Ro’s GLP-1 push with big-named celebs and Big Pharma - Modern Healthcare","headline":"Inside Ro’s GLP-1 push with big-named celebs and Big Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE51MlRlWFl5Q0QzUlY5WktoMjFXRVdEMXpNVVMyVEIxVFBKMnM2aEJVdVAzTTBMM2FhckVnaHd6amNVSEhpTS00azZQaTdYRU1XS0Ewb3NfTndJRk1DVmtUa1BlTGp5aGhqZEJ2ZktPZEdGQURHSVZOLWZ3?oc=5","date":"2025-10-09","type":"deal","source":"Axios","summary":"Pharma could still be headed for the slaughter, even if they make deals with Trump - Axios","headline":"Pharma could still be headed for the slaughter, even if they make deals with Trump","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9vS0MyMGxmc2hzT3FfdXR5TDNJS0EyOTNqR3lWSnJPaDI1SUlaN3hacDV0MmhkZmpSdzZ6NF9qaE93bHgzLWc1UXZUY01VRFpDRGJv?oc=5","date":"2025-09-18","type":"regulatory","source":"FirstWord Pharma","summary":"Friday Five – FDA says ads sell safety short, highlights from EADV and EASD, Roche's MASH cash splash…and more - FirstWord Pharma","headline":"Friday Five – FDA says ads sell safety short, highlights from EADV and EASD, Roche's MASH cash splash…and more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPcFpkR241aTR1SnZoN09GcFhlb1pyQ05DMjRSaEtZOTQxRW9XZVVGdzJaaVFZd183M2RmUFpIajNLVEZEYW83c2pLcUgyMUpUOUxMSXVXdTdnZ01qQzVrT21pc18wZTRtRTRMOWkxUkZya1dJa1FGMW5FTmtTektmSGxyVUYzTHZORUFqQl9sM05VY3RiX0NjdmxJM3A5LUJ1S2t6REFXUG9NdDB5WEhuTnZXVnRockIyQnUwTVVR?oc=5","date":"2025-06-30","type":"pipeline","source":"Fierce Pharma","summary":"Hikma to splash $1B on US production and R&D, joining branded drugmakers' investment spree - Fierce Pharma","headline":"Hikma to splash $1B on US production and R&D, joining branded drugmakers' investment spree","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPUUZoUjFpLTdkWXZVMk9sOFdlRjFfMWdqMXFZU082amNKbmQ2Y2loTlNoUXIteWpuOFFQdzVLckJmYlV6Yjh4dHVhd1pDbV96N3UwVVFyaDdhaHVfSUdTaGtYOS1tZ2JIOTdUMTBZWlI1WVVvM0l3cVl0SVRQeWF0YUxaZDBnZk52RGdKQjlvSEZfN1VjeHpKX1llTQ?oc=5","date":"2023-12-18","type":"trial","source":"BioPharma Dive","summary":"Point radiopharma drug results disappoint in prostate cancer study - BioPharma Dive","headline":"Point radiopharma drug results disappoint in prostate cancer study","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNbEtOYnZianEtR3F5NF8wSXhYdzcyXy1oejNobElaOTRJbnZ3YnNpSHFjUlVhQUhnLVNPUGxvUWljaC1UUkk0bFdGNzk1VWVHeVNUUkdqMmJEY0F5WHlESWE4c0Y3WXRtMUNMMEdxU3BSeHRZNEVkT2EwLTlfbVRJcmhWMUtYeGl6V2h0ZDFxLS1kWjEwMHR0NmhBdmp2b2hmaGJLdXNsREZNdw?oc=5","date":"2023-12-05","type":"trial","source":"Fierce Biotech","summary":"Novartis' Pluvicto readout is causing trouble for Eli Lilly’s $1.4B radiotherapy buy - Fierce Biotech","headline":"Novartis' Pluvicto readout is causing trouble for Eli Lilly’s $1.4B radiotherapy buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE1xTFB5eHJsR1JBZlJMVEI3N05ZV3Bab190TFkycDVHOTdDQ0VYVmpwZHZLZjJkUTRXYzU0UTk3TG5kSEh4Tnp5REQxSTVFM0FLTHZ5T3dKMTJPNDMwd2xZZHRuYkRLRC1mUDNVN29aVGRSeGVlc2h3?oc=5","date":"2023-08-23","type":"pipeline","source":"CVS Health","summary":"CVS Health launches Cordavis - CVS Health","headline":"CVS Health launches Cordavis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQX2s3YUdRTVU4dTlKRzJ5U2JJV0tzYWRZT0lzYWVORkJiMHQ1eEk5ay1PWUpjNUxJN0ZoZ3BSb2tlbDFJek51RlB2WXBXY1RXYkVNazh5bnNndk1lYzBlVmpRenVCcUU4MnBXb0tWTzJDREh3SUFkVkpXNG5zcjRtNkpCX2lHTThKYngtYVJ0SXJETlhnMXNMV3lGNE93NVJ1ZjhzeXZ4SkJtbjRUQzVZVTJVdlhFdzFtV2NpRnllNVRjaW5vVmRHTQ?oc=5","date":"2022-01-19","type":"patent","source":"Dallas Innovates","summary":"Mark Cuban Launches His Online Cost-Plus Pharmacy, Takes on Big Pharma with Low-Cost Generics - Dallas Innovates","headline":"Mark Cuban Launches His Online Cost-Plus Pharmacy, Takes on Big Pharma with Low-Cost Generics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFA2S2I2NzlzTVlJR2ROOXlHclN5NEtLVUhHeDBWLUd4eVliWVlJaVZxTEtlcjJkN1NqeUVQY1hKWWJwandBNFNZaGpNeXo0LW1DRDhWWndIekdhVkRTSVZuajllV2gzNUFjbXZwV01R?oc=5","date":"2018-06-28","type":"pipeline","source":"fortune.com","summary":"Jeff Bezos Just Did President Trump a Big Favor on Drug Pricing - fortune.com","headline":"Jeff Bezos Just Did President Trump a Big Favor on Drug Pricing","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}